# Where the margin lives: dissecting value capture across the chain
A hospital pays roughly $10,000 for a coronary drug-eluting stent system. The device maker did not keep $10,000. It may have booked $7,000 in revenue, spent $1,500 making it, and handed $1,000 to a distributor and hundreds more in rebates to the hospital's purchasing group. The rest evaporated across a chain of players, each fighting to keep a bigger slice.
That fight is the real subject of this lesson. In biotech and medtech, list prices are fiction. What matters is who captures the margin after every hand takes its cut.
We will follow two products end to end.
Both have high gross margins. The difference is *who else lives off the price*.
Let us build it up. These are illustrative estimates consistent with publicly reported medtech economics; exact splits vary by product and contract.
| Layer | Approx. amount | Who captures it |
|---|---|---|
| Distributor / sales rep margin | $1,000 | Distributor or in-house sales force |
| GPO / hospital rebate | $700 | Hospital or purchasing group |
| Manufacturer gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.View full definition → retained | $6,800 | The device maker |
Gross marginGross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.View full definition → = revenue minus COGS. If the maker recognizes $8,300 in net revenue after the rebate and COGS is $1,500, gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.View full definition → is about 82 percent. That is typical for large-cap medtech (Medtronic, Boston Scientific, Stryker routinely report 65 to 75 percent gross margins across mixed portfolios).
The GPO (Group Purchasing Organization: an entity that negotiates prices on behalf of many hospitals) is the key power broker in US medtech. Three GPOs (Vizient, Premier, HealthTrust) cover a large majority of US hospital purchasing. They extract rebates and administrative fees from manufacturers in exchange for access.
The device rep matters more than outsiders expect. For implants, the sales rep is often physically in the operating room advising on sizing. That clinical embeddingembeddingAn embedding is a numerical vector that represents data (text, images, or items) in a way that captures meaning, so similar items sit close together in space.View full definition → makes switching costly and lets incumbents defend price. This is why challengers with a cheaper stent still struggle: the incumbent owns the surgeon relationship.
Now the drug. Marginal cost to produce one more year of a monoclonal antibody might be a few thousand dollars. So gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.View full definition → looks enormous. But the pharmaceutical chain inserts intermediaries the device world does not have.
Here is a simplified US flow for a drug with a $100,000 list price (formally the WAC: Wholesaler Acquisition CostAcquisition CostCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.View full definition →).
The PBM (Pharmacy Benefit Manager: a middleman that manages drug coverage for insurers and employers) is the pivotal player. The three largest (CVS Caremark, Express Scripts / Cigna, OptumRx) control the majority of US prescription volume. They decide formulary placement (the list of covered drugs) and negotiate rebates.
This creates the gross-to-net bubble: the widening gap between list price and net price. A drug can raise its list price while its net price falls, because the extra list dollars flow to rebates the PBM and payer capture. Patients whose copay is tied to list price lose. The manufacturer may not gain.
The Kaiser Family Foundation maintains accessible primers on how this pricing flows: KFF on prescription drug pricing.
For physician-administered drugs and devices in the US, providers are often paid on buy-and-bill: the hospital or clinic buys the product, administers it, then bills the payer.
Medicare Part B historically reimburses many such drugs at ASP + 6% (Average Sales Price plus a 6 percent markup; the effective figure is lower after federal sequestration, closer to 4.3 percent). That markup is a reimbursement spread: the provider keeps the difference between acquisition costacquisition costCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.View full definition → and reimbursement.
Worked example:
This creates a distortion: a higher-priced drug yields a bigger absolute spread, so the payment design can nudge toward expensive products. Policymakers know this, which is why reforms keep targeting it.
In Europe the fight looks different because governments, not PBMs, hold the leverage.
Net effect: in Europe the payer-state captures more of the value, and manufacturers accept lower prices for guaranteed volume. In the US, intermediaries (PBMs, GPOs, wholesalers, providers) each carve out margin, and list prices run higher.
Knowledge check
1. The lesson argues that in biotech and medtech 'list prices are fiction.' What is the core reasoning behind this claim?
2. Why does the lesson contrast a physical device with a biologic when analyzing value capture?
3. A biologic has a tiny marginal cost per dose but huge fixed R&D, while the device has moderate manufacturing cost. What does this distinction imply about interpreting their gross margins?
4. Select ALL correct answers about how value is captured across the device chain.
Select all the correct answers.
5. Select ALL correct answers about analyzing where margin 'lives' in a value chain.
Select all the correct answers.
Follow the power, not the price.
Pharma manufacturers hold pricing power only while a molecule has patent and data exclusivity protection. The cliff is brutal. When a biologic loses exclusivity, biosimilars (near-copies of a biologic, cheaper but not identical) erode share. Humira (adalimumab), once the top-selling drug globally, faced multiple US biosimilars from 2023 onward and lost meaningful net revenue. That is competitive dynamics in action: the incumbent's margin transfers partly to payers and partly to biosimilar challengers like Amgen and Sandoz.
PBMs may be the strongest US players in the drug chain. Their consolidation with insurers (CVS owns Caremark and Aetna; Cigna owns Express Scripts) means one entity spans insurance, benefit management, and pharmacy. That vertical integration lets them capture spread at multiple points. Expect continued regulatory scrutiny from the FTC (Federal Trade Commission), which has publicly challenged PBM practices.
Medtech incumbents defend margin through clinical lock-in (the rep in the OR), bundled contracts, and iterative product cycles rather than radical innovation. Challengers win by targeting niches incumbents ignore, then getting acquired. The dominant medtech exit is acquisition, not independence.
Distributors and GPOs run on scale and thin percentage margins, but their gatekeeping over hospital access gives them structural leverage over manufacturers who need shelf space.
Suppliers (contract manufacturers, specialty component makers) usually hold the least power, except when they are single-source for a critical input, at which point the balance flips sharply.
Value capture is a negotiation, not an accounting outcome. Each player's margin reflects how easily others can bypass them.
When you evaluate any biotech or medtech business, mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.View full definition → the chain and ask at every node: *what would it cost the next player to remove this one?* The answer tells you where the margin lives, and whether it will stay there.